智通财经APP讯,复锐医疗科技(01696)发布公告,公司知悉市场对其再授权产品RT002(中国境内商标达希斐®,英文商标 DAXXIFY®,通用名DaxibotulinumtoxinA-lanm)于中国内地的商业化进展持续关注。
公司仅此说明,于本公告日期,该产品在中国内地的商业化工作正稳步推进。监管申报、市场准入及专业团队的建设等相关业务准备工作均有序开展。公司对该产品在中国市场的应用前景充满信心,并将根据实际进展适时披露进一步信息。
智通财经APP讯,复锐医疗科技(01696)发布公告,公司知悉市场对其再授权产品RT002(中国境内商标达希斐®,英文商标 DAXXIFY®,通用名DaxibotulinumtoxinA-lanm)于中国内地的商业化进展持续关注。
公司仅此说明,于本公告日期,该产品在中国内地的商业化工作正稳步推进。监管申报、市场准入及专业团队的建设等相关业务准备工作均有序开展。公司对该产品在中国市场的应用前景充满信心,并将根据实际进展适时披露进一步信息。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.